CAG
AVNS

Crestwood Advisors Group’s Avanos Medical AVNS Stock Holding History

Crestwood Advisors Group’s Portfolio AVNS Stock Details AVNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,656
Closed -$64K – 177
2017
Q1 		$64K Buy
+1,656
New +$64.5K 0.01% 225

Other funds holding AVNS

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PIM
Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Crestwood Advisors Group's AVNS Position: Q2 2017 in Review

Crestwood Advisors Group sold out of Avanos Medical (AVNS) in Q2 2017, closing a stake of 1,656 shares — an estimated $64K sold.

Crestwood Advisors Group first reported a position in AVNS in Q1 2017 and held it in 1 quarter. The position peaked at $64K in Q1 2017. 328 funds tracked by Wall St. Rank hold AVNS as of Q2 2017.

  • Crestwood Advisors Group reported no remaining Avanos Medical position as of Q2 2017 after selling out during the quarter.
  • Crestwood Advisors Group sold 1,656 Avanos Medical shares in Q2 2017, an estimated $64K.
  • Crestwood Advisors Group first reported a position in Avanos Medical in Q1 2017 and held it in 1 quarter.
  • Crestwood Advisors Group's Avanos Medical position peaked at $64K in Q1 2017.
  • 328 funds tracked by Wall St. Rank held Avanos Medical as of Q2 2017.

Based on Crestwood Advisors Group's 13F filing for Q2 2017, filed 31 Jul 2017.